Literature DB >> 16326097

Borderline tumours of the ovary and fertility.

P Morice1.   

Abstract

Standard management of borderline ovarian tumours (BOT) is historically radical and based on hysterectomy, bilateral salpingo-oophorectomy and peritoneal staging. But, as 1/3 of BOTs are diagnosed in patients aged less than 40 years, treatments preserving fertility-potential (with preservation of the uterus and at least part of one ovary) has seen great developments in the last decade. Such treatments increase the rate of recurrences (between 15% and 35% depending on the type of conservative surgery), but without any impact on patient survival as most recurrent diseases are of the borderline type, easily curable and with excellent prognosis. The spontaneous pregnancy rate is nearly 50%. In case of persistent infertility, it seems that the use of ovarian induction or in vitro fertilization procedures could be proposed in selected cases. Follow-up is essential and based on clinical examination and routine ultrasonography. The interest of completion surgery (removal of the retained ovary) in patients who obtained pregnancy remains debated. In conclusion, conservative management of at least part of one ovary and uterus could be safely proposed at least to patients with early stage BOT, in order to preserve fertility-potential. The rate of recurrence is increased but without any impact on survival.

Entities:  

Mesh:

Year:  2005        PMID: 16326097     DOI: 10.1016/j.ejca.2005.07.029

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  16 in total

Review 1.  Diagnosis, treatment, and follow-up of borderline ovarian tumors.

Authors:  Daniela Fischerova; Michal Zikan; Pavel Dundr; David Cibula
Journal:  Oncologist       Date:  2012-09-28

2.  A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002: centralized pathology review and overall survival compared with the general population.

Authors:  Charlotte Gerd Hannibal; Russell Vang; Jette Junge; Kirsten Frederiksen; Anette Kjaerbye-Thygesen; Klaus Kaae Andersen; Ann Tabor; Robert J Kurman; Susanne K Kjaer
Journal:  Gynecol Oncol       Date:  2014-06-10       Impact factor: 5.482

3.  Laparoscopic restaging of borderline ovarian tumors.

Authors:  E Daraï; L Tulpin; H Prugnolle; A Cortez; G Dubernard
Journal:  Surg Endosc       Date:  2007-05-19       Impact factor: 4.584

4.  Invasive recurrence of an intestinal-type mucinous epithelial neoplasm of low malignant potential: case report and review of the literature.

Authors:  S Cosyns; M Leyder; C Bourgain; P De Sutter
Journal:  Case Rep Oncol       Date:  2011-08-31

5.  Ovarian stimulation for emergency fertility preservation in cancer patients: A case series study.

Authors:  Batool Hossein Rashidi; Ensiyeh Shahrokh Tehrani; Firouzeh Ghaffari
Journal:  Gynecol Oncol Rep       Date:  2014-10-01

6.  Spontaneously Ruptured Paraovarian Tumor of Borderline Malignancy with Extremely Elevated Serum Carbohydrate Antigen 125 (CA125) Levels: A Comparison of the Imaging and Pathological Features.

Authors:  Akiko Kajiyama; Hiromi Edo; Chiaki Takeya; Kaneyuki Kubushiro; Toshiaki Oharaseki; Tatsuya Gomi
Journal:  Am J Case Rep       Date:  2017-08-24

7.  Identification of factors that impact recurrence in patients with borderline ovarian tumors.

Authors:  Xi Chen; Chenyan Fang; Tao Zhu; Ping Zhang; Aijun Yu; Shihua Wang
Journal:  J Ovarian Res       Date:  2017-04-04       Impact factor: 4.234

Review 8.  The Putative Role of TP53 Alterations and p53 Expression in Borderline Ovarian Tumors - Correlation with Clinicopathological Features and Prognosis: A Mini-Review.

Authors:  Andrzej Semczuk; Marek Gogacz; Anna Semczuk-Sikora; Maciej Jóźwik; Tomasz Rechberger
Journal:  J Cancer       Date:  2017-08-22       Impact factor: 4.207

9.  Borderline paratubal cyst: a case report.

Authors:  Fatima Zohra Fdili Alaoui; Hinde El Fatemi; Hekmat Chaara; Molay Abdilah Melhouf; Afaf Amarti
Journal:  Pan Afr Med J       Date:  2012-11-16

Review 10.  Controversies in borderline ovarian tumors.

Authors:  Seok Ju Seong; Da Hee Kim; Mi Kyoung Kim; Taejong Song
Journal:  J Gynecol Oncol       Date:  2015-09-23       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.